{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:13:27Z","timestamp":1786738407632,"version":"build-2736575974"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["contrat d\\u2019Interface Inserm 2024"],"award-info":[{"award-number":["contrat d\\u2019Interface Inserm 2024"]}],"id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008765","name":"Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de Gastro-Ent\u00e9rologie","doi-asserted-by":"publisher","award":["COMAD 2022"],"award-info":[{"award-number":["COMAD 2022"]}],"id":[{"id":"10.13039\/501100008765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008765","name":"Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de Gastro-Ent\u00e9rologie","doi-asserted-by":"publisher","award":["COMAD 2026"],"award-info":[{"award-number":["COMAD 2026"]}],"id":[{"id":"10.13039\/501100008765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["PAIR obesit\\u00E9 N\\u00B018713"],"award-info":[{"award-number":["PAIR obesit\\u00E9 N\\u00B018713"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["\\u00E9quipe labellis\\u00E9e 2023"],"award-info":[{"award-number":["\\u00E9quipe labellis\\u00E9e 2023"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["JCJC 2023"],"award-info":[{"award-number":["JCJC 2023"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["2022 SYSTHEC"],"award-info":[{"award-number":["2022 SYSTHEC"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","award":["2023 CSS13 HBV-LIRAGE ECTZ232901"],"award-info":[{"award-number":["2023 CSS13 HBV-LIRAGE ECTZ232901"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006678","name":"Association Fran\u00e7aise pour l&apos;Etude du Foie","doi-asserted-by":"publisher","award":["2022 projet radio-mol\\u00E9culaire"],"award-info":[{"award-number":["2022 projet radio-mol\\u00E9culaire"]}],"id":[{"id":"10.13039\/501100006678","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jhepr.2026.101991","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:37:04Z","timestamp":1786664224000},"page":"101991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of rare primary liver cancers: combined hepato-cholangiocarcinoma and fibrolamellar hepatocellular carcinoma"],"prefix":"10.1016","author":[{"given":"Matteo","family":"Gallant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3304-2106","authenticated-orcid":false,"given":"Marie","family":"Decraecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5117-4842","authenticated-orcid":false,"given":"Marianne","family":"Ziol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Calderaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7464-3939","authenticated-orcid":false,"given":"Maxime","family":"Ronot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Zucman-Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-9353","authenticated-orcid":false,"given":"Jean-Charles","family":"Nault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101991_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2024.06.004","article-title":"Rare primary liver cancers: An EASL position paper","author":"Wege","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101991_bib2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hep.29789","article-title":"cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation","volume":"68","author":"Brunt","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101991_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12957-019-1586-8","article-title":"Combined hepatocellular-cholangiocarcinoma: a population level analysis of incidence and mortality trends","volume":"17","author":"Wang","year":"2019","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.jhepr.2026.101991_bib4","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.hpb.2016.07.006","article-title":"Mixed hepatocellular and cholangiocarcinoma: a rare tumor with a mix of parent phenotypic characteristics","volume":"18","author":"Bergquist","year":"2016","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jhepr.2026.101991_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/hepr.13438","article-title":"Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan","volume":"50","author":"Kudo","year":"2020","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhepr.2026.101991_bib6","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/lt.23897","article-title":"Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor","volume":"20","author":"Garancini","year":"2014","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhepr.2026.101991_bib7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11605-015-3045-3","article-title":"Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma","volume":"20","author":"Yoon","year":"2016","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.jhepr.2026.101991_bib8","article-title":"New insights into the pathophysiology and clinical care of rare primary liver cancers","volume":"3","author":"Gigante","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101991_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/3002480","article-title":"Morbidity, Prognostic Factors, and Competing Risk Nomogram for Combined Hepatocellular-Cholangiocarcinoma","volume":"2021","author":"Chen","year":"2021","journal-title":"J Oncol"},{"key":"10.1016\/j.jhepr.2026.101991_bib10","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/s41467-018-03276-y","article-title":"Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2026.101991_bib11","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.jhep.2022.07.029","article-title":"Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling","volume":"77","author":"Rosenberg","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101991_bib12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ajpath.2024.08.014","article-title":"Morphomolecular Pathology and Genomic Insights into the Cells of Origin of Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma","volume":"195","author":"Guest","year":"2025","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhepr.2026.101991_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2017.05.009","article-title":"Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma","author":"Chaisaingmongkol","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2026.101991_bib14","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2017.01.010","article-title":"Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity","volume":"66","author":"Moeini","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101991_bib15","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.ccell.2019.04.007","article-title":"Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes","volume":"35","author":"Xue","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2026.101991_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.106048","article-title":"Mutational patterns and ancestry-linked profiles in a large hepatocellular carcinoma and combined hepatocellular-cholangiocarcinoma cohort","volume":"11","author":"Gerdes","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.jhepr.2026.101991_bib17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/path.5243","article-title":"Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma","volume":"248","author":"Joseph","year":"2019","journal-title":"J Pathol"},{"key":"10.1016\/j.jhepr.2026.101991_bib18","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1038\/ncomms3218","article-title":"High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions","volume":"4","author":"Nault","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2026.101991_bib19","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/hep.32135","article-title":"Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas","volume":"75","author":"An","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101991_bib20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/PAS.0000000000001201","article-title":"Cholangiolocellular Carcinoma With \u201cDuctal Plate Malformation\u201d Pattern May Be Characterized by ARID1A Genetic Alterations","volume":"43","author":"Sasaki","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jhepr.2026.101991_bib21","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.jhep.2022.07.019","article-title":"Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma","volume":"77","author":"Calderaro","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101991_bib22","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1158\/1078-0432.CCR-21-1219","article-title":"Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy","volume":"28","author":"Nguyen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhepr.2026.101991_bib23","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.hbpd.2020.07.004","article-title":"Combined hepatocellular-cholangiocarcinoma: An update on epidemiology, classification, diagnosis and management","volume":"19","author":"Schizas","year":"2020","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.jhepr.2026.101991_bib24","doi-asserted-by":"crossref","first-page":"190","DOI":"10.15403\/jgld-4893","article-title":"Clinical Characterization of HCC\/CCA Mixed Cancers in a Population-based Cohort","volume":"32","author":"Teufel","year":"2023","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.jhepr.2026.101991_bib25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12885-016-2156-x","article-title":"Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography","volume":"16","author":"Li","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhepr.2026.101991_bib26","doi-asserted-by":"crossref","first-page":"7325","DOI":"10.3748\/wjg.v26.i46.7325","article-title":"Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"26","author":"Yang","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101991_bib27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10396-017-0834-1","article-title":"Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma","volume":"45","author":"Huang","year":"2018","journal-title":"J Med Ultrason (2001)"},{"key":"10.1016\/j.jhepr.2026.101991_bib28","article-title":"Current advances and future directions in combined hepatocellular and cholangiocarcinoma","volume":"12","author":"Zhang","year":"2024","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"10.1016\/j.jhepr.2026.101991_bib29","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3390\/biomedicines10081826","article-title":"Combined Hepatocellular-Cholangiocarcinoma: An Update on Pathology and Diagnostic Approach","volume":"10","author":"Choi","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.jhepr.2026.101991_bib30","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1007\/s00261-015-0433-9","article-title":"Biphenotypic hepatic tumors: imaging findings and review of literature","volume":"40","author":"Wells","year":"2015","journal-title":"Abdom Imaging"},{"key":"10.1016\/j.jhepr.2026.101991_bib31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.29271\/jcpsp.2020.03.263","article-title":"Diagnostic Value of Serum Biomarkers in Combined Hepatocelluar-Cholangiocarcinoma","volume":"30","author":"Chen","year":"2020","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.jhepr.2026.101991_bib32","article-title":"CEUS and CT\/MRI LI-RADS in Association With Serum Biomarkers for Differentiation of Combined Hepatocellular-Cholangiocarcinoma From Hepatocellular Carcinoma","volume":"12","author":"Zhou","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhepr.2026.101991_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2022.110415","article-title":"Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma","volume":"154","author":"Wen","year":"2022","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.jhepr.2026.101991_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.107279","article-title":"Meta-analysis of prognostic factors for overall survival and disease-free survival among resected patients with combined hepatocellular carcinoma and cholangiocarcinoma","volume":"50","author":"Lv","year":"2024","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jhepr.2026.101991_bib35","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1148\/radiol.2018181494","article-title":"Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients","volume":"289","author":"Chernyak","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.jhepr.2026.101991_bib36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2214\/AJR.15.14997","article-title":"Imaging Features of Biphenotypic Primary Liver Carcinoma (Hepatocholangiocarcinoma) and the Potential to Mimic Hepatocellular Carcinoma: LI-RADS Analysis of CT and MRI Features in 61 Cases","volume":"207","author":"Potretzke","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jhepr.2026.101991_bib37","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00330-018-5605-x","article-title":"Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging","volume":"29","author":"Jeon","year":"2019","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jhepr.2026.101991_bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.17998\/jlc.21.1.12","article-title":"Update on Pathologic and Radiologic Diagnosis of Combined Hepatocellular-Cholangiocarcinoma","volume":"21","author":"Rhee","year":"2021","journal-title":"J Liver Cancer"},{"key":"10.1016\/j.jhepr.2026.101991_bib39","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00330-025-11780-1","article-title":"Differentiating combined hepatocellular-cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma with MRI and tumor markers: a multi-center study","volume":"36","author":"He","year":"2026","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jhepr.2026.101991_bib40","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1111\/liv.14261","article-title":"Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular-cholangiocarcinoma","volume":"39","author":"Gigante","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.101991_bib41","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1055\/a-2730-9074","article-title":"Combined Hepatocellular-Cholangiocarcinoma: A Clinical and Molecular Review","volume":"45","author":"Xu","year":"2025","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhepr.2026.101991_bib42","article-title":"Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma","volume":"5","author":"Murugesan","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jhepr.2026.101991_bib43","doi-asserted-by":"crossref","first-page":"8290","DOI":"10.1038\/s41467-023-43749-3","article-title":"Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma","volume":"14","author":"Calderaro","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2026.101991_bib44","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3390\/cancers15030774","article-title":"Surgical Strategies for Combined Hepatocellular-Cholangiocarcinoma (cHCC-CC)","volume":"15","author":"Bahra","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhepr.2026.101991_bib45","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/ags3.12555","article-title":"Long-term outcomes of laparoscopic versus open liver resection for intrahepatic combined hepatocellular-cholangiocarcinoma with propensity score matching","volume":"6","author":"Lee","year":"2022","journal-title":"Ann Gastroenterol Surg"},{"key":"10.1016\/j.jhepr.2026.101991_bib46","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00464-022-09579-y","article-title":"Perioperative and oncologic outcomes of laparoscopic versus open liver resection for combined hepatocellular-cholangiocarcinoma: a propensity score matching analysis","volume":"37","author":"Song","year":"2023","journal-title":"Surg Endosc"},{"key":"10.1016\/j.jhepr.2026.101991_bib47","doi-asserted-by":"crossref","first-page":"635","DOI":"10.4254\/wjh.v9.i13.635","article-title":"Importance of surgical margin in the outcomes of hepatocholangiocarcinoma","volume":"9","author":"Ma","year":"2017","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101991_bib48","doi-asserted-by":"crossref","first-page":"5968","DOI":"10.3748\/wjg.v28.i41.5968","article-title":"Prognostic analysis of patients with combined hepatocellular-cholangiocarcinoma after radical resection: A retrospective multicenter cohort study","volume":"28","author":"Zhang","year":"2022","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101991_bib49","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.surg.2023.09.040","article-title":"Combined hepatocellular-cholangiocarcinoma compared to hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Different survival, similar recurrence: Report of a large study on repurposed databases with propensity score matching","volume":"175","author":"Amory","year":"2024","journal-title":"Surgery"},{"key":"10.1016\/j.jhepr.2026.101991_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.110279","article-title":"Impact of hepatocellular carcinoma-related prognostic factors on combined hepatocellular cholangiocarcinoma: A surgical cohort study","volume":"51","author":"Chen","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jhepr.2026.101991_bib51","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/jso.23289","article-title":"Transplantation versus resection for patients with combined hepatocellular carcinoma-cholangiocarcinoma","volume":"107","author":"Groeschl","year":"2013","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.jhepr.2026.101991_bib52","doi-asserted-by":"crossref","DOI":"10.4240\/wjgs.v17.i5.105783","article-title":"Liver transplantation for combined hepatocellular cholangiocarcinoma: Current evidence, selection criteria, and therapeutic controversies","volume":"17","author":"Zhou","year":"2025","journal-title":"World J Gastrointest Surg"},{"key":"10.1016\/j.jhepr.2026.101991_bib53","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/lt.25737","article-title":"Analysis of Liver Resection Versus Liver Transplantation on Outcome of Small Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma in the Setting of Cirrhosis","volume":"26","author":"De Martin","year":"2020","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhepr.2026.101991_bib54","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.hpb.2015.10.001","article-title":"Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database","volume":"18","author":"Vilchez","year":"2016","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jhepr.2026.101991_bib55","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jamcollsurg.2020.11.017","article-title":"Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors","volume":"232","author":"Dageforde","year":"2021","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.jhepr.2026.101991_bib56","doi-asserted-by":"crossref","first-page":"8857","DOI":"10.3390\/jcm14248857","article-title":"Outcomes of Liver Transplantation in Incidental Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma: An Exceptional Perspective from a Single-Center Experience","volume":"14","author":"Ma","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.jhepr.2026.101991_bib57","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1148\/radiol.09091076","article-title":"Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization","volume":"255","author":"Kim","year":"2010","journal-title":"Radiology"},{"key":"10.1016\/j.jhepr.2026.101991_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198138","article-title":"The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection","volume":"13","author":"Na","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2026.101991_bib59","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00270-017-1648-7","article-title":"Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma","volume":"40","author":"Chan","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jhepr.2026.101991_bib60","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000508386","article-title":"Yttrium-90 Radioembolization Therapy for Combined Hepatocellular and Cholangiocarcinoma","volume":"7","author":"Badar","year":"2020","journal-title":"Gastrointest Tumors"},{"key":"10.1016\/j.jhepr.2026.101991_bib61","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jvir.2019.09.028","article-title":"Outcomes of Yttrium-90 Radioembolization for Unresectable Combined Biphenotypic Hepatocellular-Cholangiocarcinoma","volume":"31","author":"Malone","year":"2020","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jhepr.2026.101991_bib62","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00423-023-02858-9","article-title":"Radiofrequency ablation versus liver resection and liver transplantation for small combined hepatocellular-cholangiocarcinoma stratified by tumor size","volume":"408","author":"Peng","year":"2023","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.jhepr.2026.101991_bib63","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1159\/000525488","article-title":"Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma","volume":"11","author":"Gigante","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2026.101991_bib64","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/liv.14813","article-title":"Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma","volume":"41","author":"Kim","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.101991_bib65","doi-asserted-by":"crossref","first-page":"347","DOI":"10.21037\/jgo.2017.03.03","article-title":"Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy","volume":"8","author":"Rogers","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.jhepr.2026.101991_bib66","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1111\/cas.13656","article-title":"Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma","volume":"109","author":"Kobayashi","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jhepr.2026.101991_bib67","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/bjc.2017.413","article-title":"Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study","volume":"118","author":"Salimon","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2026.101991_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100783","article-title":"Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma-a European multicenter cohort","volume":"8","author":"Pomej","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.jhepr.2026.101991_bib69","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ueg2.12503","article-title":"Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective study","volume":"12","author":"Gigante","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.jhepr.2026.101991_bib70","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.21873\/anticanres.17499","article-title":"Efficacy of Lenvatinib and Atezolizumab Bevacizumab Combination Therapy in Patients With Combined Hepatocellular-cholangiocarcinoma","volume":"45","author":"Tanabe","year":"2025","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jhepr.2026.101991_bib71","doi-asserted-by":"crossref","first-page":"7547","DOI":"10.1007\/s00432-023-04704-3","article-title":"Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma","volume":"149","author":"Jang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101991_bib72","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.jhep.2023.08.017","article-title":"Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab\/bevacizumab","volume":"79","author":"Limousin","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101991_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2026.03.019","article-title":"Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French Genomic Medicine Initiative","author":"Campani","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101991_bib74","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/1097-0142(19800715)46:2<372::AID-CNCR2820460227>3.0.CO;2-S","article-title":"Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features","volume":"46","author":"Craig","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/j.jhepr.2026.101991_bib75","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/hep.20096","article-title":"Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study","volume":"39","author":"El-Serag","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101991_bib76","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s10620-020-06135-3","article-title":"Fibrolamellar Hepatocellular Carcinoma: A Population-Based Observational Study","volume":"66","author":"Ramai","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2026.101991_bib77","first-page":"3","article-title":"Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium","volume":"6","author":"Ang","year":"2013","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.jhepr.2026.101991_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2025.102629","article-title":"Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma: A Case of Rapid Neurologic Recovery Following Cytoreductive Surgery","volume":"15","author":"Schoeneich","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jhepr.2026.101991_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2022.100847","article-title":"Refractory Hyperammonemic encephalopathy in Fibrolamellar hepatocellular carcinoma, a case report and literature review","volume":"46","author":"Ahmed","year":"2022","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.jhepr.2026.101991_bib80","article-title":"Molecular Basis of Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma","volume":"15","author":"Surjan","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jhepr.2026.101991_bib81","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.1249484","article-title":"Detection of a Recurrent DNAJB1-PRKACA Chimeric Transcript in Fibrolamellar Hepatocellular Carcinoma","volume":"343","author":"Honeyman","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2026.101991_bib82","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/modpathol.2015.4","article-title":"DNAJB1-PRKACA is specific for fibrolamellar carcinoma","volume":"28","author":"Graham","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jhepr.2026.101991_bib83","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/modpathol.2017.103","article-title":"Molecular testing for the clinical diagnosis of fibrolamellar carcinoma","volume":"31","author":"Graham","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jhepr.2026.101991_bib84","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/hep.29719","article-title":"Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion","volume":"68","author":"Graham","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101991_bib85","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1053\/j.gastro.2019.10.028","article-title":"Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas and Bile Duct","volume":"158","author":"Singhi","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101991_bib86","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1053\/j.gastro.2014.12.028","article-title":"Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma","volume":"148","author":"Cornella","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101991_bib87","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1002\/hep.27018","article-title":"Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature","volume":"59","author":"Malouf","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101991_bib88","doi-asserted-by":"crossref","first-page":"E5916","DOI":"10.1073\/pnas.1424894112","article-title":"Transcriptomic characterization of fibrolamellar hepatocellular carcinoma","volume":"112","author":"Simon","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhepr.2026.101991_bib89","article-title":"Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1","volume":"84","author":"M","year":"2024","journal-title":"Cancer Research"},{"key":"10.1016\/j.jhepr.2026.101991_bib90","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1158\/1078-0432.CCR-22-1851","article-title":"Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA","volume":"29","author":"Neumayer","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhepr.2026.101991_bib91","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1053\/j.gastro.2017.09.008","article-title":"CRISPR\/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma","volume":"153","author":"Engelholm","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101991_bib92","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1158\/2159-8290.CD-24-0634","article-title":"DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2\/p300-Mediated Transcriptional Reprogramming","volume":"15","author":"Gritti","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.101991_bib93","article-title":"BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA","author":"Hirsch","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101991_bib94","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jhep.2011.07.018","article-title":"GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation","volume":"56","author":"Nault","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.jhepr.2026.101991_bib95","article-title":"Correct diagnosis of patients with fibrolamellar carcinoma: A Dutch nationwide study","author":"Furumaya","year":"2025","journal-title":"Histopathology"},{"key":"10.1016\/j.jhepr.2026.101991_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2026.01.015","article-title":"Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma","author":"Nault","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101991_bib97","article-title":"Procalcitonin as a potential tumor marker for fibrolamellar hepatocellular carcinoma: Insights from three patients and a literature review","volume":"13","author":"\u00d6zden","year":"2026","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jhepr.2026.101991_bib98","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0140-6736(11)61022-2","article-title":"Liver mass in a young adult","volume":"378","author":"Brunel","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.101991_bib99","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1007\/s12029-021-00731-w","article-title":"High-Level Procalcitonin in Patient with Mixed Fibrolamellar Hepatocellular Carcinoma: A Case Report and Literature Review","volume":"53","author":"Akbulut","year":"2022","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.jhepr.2026.101991_bib100","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/jclinpath-2014-202807","article-title":"Procalcitonin","volume":"68","author":"Davies","year":"2015","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jhepr.2026.101991_bib101","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0009-8981(02)00101-8","article-title":"Pathobiochemistry and clinical use of procalcitonin","volume":"323","author":"Meisner","year":"2002","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jhepr.2026.101991_bib102","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1148\/radiology.213.2.r99nv31352","article-title":"Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases","volume":"213","author":"Ichikawa","year":"1999","journal-title":"Radiology"},{"key":"10.1016\/j.jhepr.2026.101991_bib103","doi-asserted-by":"crossref","first-page":"544","DOI":"10.2214\/AJR.13.11117","article-title":"Imaging features of fibrolamellar hepatocellular carcinoma","volume":"202","author":"Ganeshan","year":"2014","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jhepr.2026.101991_bib104","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40644-018-0143-y","article-title":"Imaging features of fibrolamellar hepatocellular carcinoma in gadoxetic acid-enhanced MRI","volume":"18","author":"Palm","year":"2018","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.jhepr.2026.101991_bib105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2559.1990.tb00679.x","article-title":"Abundant expression of cytokeratin 7 in fibrolamellar carcinoma of the liver","volume":"17","author":"Van Eyken","year":"1990","journal-title":"Histopathology"},{"key":"10.1016\/j.jhepr.2026.101991_bib106","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/modpathol.2010.105","article-title":"Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation","volume":"23","author":"Ward","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jhepr.2026.101991_bib107","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/modpathol.2010.207","article-title":"Fibrolamellar carcinomas are positive for CD68","volume":"24","author":"Ross","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jhepr.2026.101991_bib108","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001700","article-title":"Clinical guideline for the diagnosis and treatment of fibrolamellar carcinoma","author":"O\u2019Neill","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101991_bib109","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12957-020-01855-2","article-title":"Clinical features and surgical outcomes of fibrolamellar hepatocellular carcinoma: retrospective analysis of a single-center experience","volume":"18","author":"Lemekhova","year":"2020","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.jhepr.2026.101991_bib110","first-page":"46","article-title":"Curative lung metastectomy and complete pathological response after neo-adjuvant GEMOX chemotherapy for relapse fibrolamellar hepatocellular carcinoma","volume":"73","author":"Eng","year":"2018","journal-title":"Med J Malaysia"},{"key":"10.1016\/j.jhepr.2026.101991_bib111","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4240\/wjgs.v9.i2.61","article-title":"Clinicopathological features and surgical outcome of patients with fibrolamellar hepatocellular carcinoma (experience with 22 patients over a 15-year period)","volume":"9","author":"Wahab","year":"2017","journal-title":"World J Gastrointest Surg"},{"key":"10.1016\/j.jhepr.2026.101991_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102162","article-title":"Fibrolamellar hepatocellular carcinoma: An epidemiologic and 5-year cancer survival assessment based off SEER data","volume":"47","author":"Aloysius","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101991_bib113","doi-asserted-by":"crossref","first-page":"847","DOI":"10.21873\/anticanres.14017","article-title":"Predictors of Outcome in Patients With Fibrolamellar Carcinoma: Analysis of the National Cancer Database","volume":"40","author":"Assi","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jhepr.2026.101991_bib114","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/jso.24515","article-title":"Liver transplantation for fibrolamellar hepatocellular carcinoma: A national perspective","volume":"115","author":"Atienza","year":"2017","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.jhepr.2026.101991_bib115","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1159\/000524872","article-title":"Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report","volume":"45","author":"Kang","year":"2022","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.jhepr.2026.101991_bib116","doi-asserted-by":"crossref","DOI":"10.14309\/crj.2016.79","article-title":"Successful Liver Transplantation for Hyperammonemic Fibrolamellar Hepatocellular Carcinoma","volume":"3","author":"Alsina","year":"2016","journal-title":"ACG Case Rep J"},{"key":"10.1016\/j.jhepr.2026.101991_bib117","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s00270-018-1903-6","article-title":"Fibrolamellar Hepatocellular Carcinoma: Treatment with Yttrium-90 and Subsequent Surgical Resection","volume":"41","author":"Mafeld","year":"2018","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jhepr.2026.101991_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijscr.2022.106980","article-title":"Trans-arterial therapy for Fibrolamellar carcinoma: A case report and literature review","volume":"94","author":"Bernon","year":"2022","journal-title":"Int J Surg Case Rep"},{"key":"10.1016\/j.jhepr.2026.101991_bib119","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.dld.2025.04.016","article-title":"Response to systemic treatments and survival of fibrolamellar carcinomas: An AGEO-SFCE French multicenter retrospective cohort","volume":"57","author":"Ye-Tran","year":"2025","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2026.101991_bib120","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005620","article-title":"Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab","volume":"10","author":"Berger","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhepr.2026.101991_bib121","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1200\/JCO.2003.10.103","article-title":"Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma","volume":"21","author":"Patt","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101991_bib122","doi-asserted-by":"crossref","first-page":"e1837","DOI":"10.1634\/theoncologist.2020-0093","article-title":"Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma","volume":"25","author":"Abou-Alfa","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jhepr.2026.101991_bib123","first-page":"58","article-title":"Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma","volume":"14","author":"Abou-Alfa","year":"2025","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2026.101991_bib124","doi-asserted-by":"crossref","first-page":"925-e1603","DOI":"10.1634\/theoncologist.2020-0367","article-title":"A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma","volume":"25","author":"El Dika","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jhepr.2026.101991_bib125","article-title":"DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma","volume":"5","author":"Kirk","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jhepr.2026.101991_bib126","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1038\/s41467-022-33746-3","article-title":"The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma","volume":"13","author":"Bauer","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2026.101991_bib127","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","article-title":"Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial","volume":"30","author":"Yarchoan","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.101991_bib128","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1367450","article-title":"FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion","volume":"14","author":"Hackenbruch","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhepr.2026.101991_bib129","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1158\/2159-8290.CD-20-0872","article-title":"Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening","volume":"11","author":"Lalazar","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.101991_bib130","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2025.10.006","article-title":"Overcoming CXCR4-Mediated T-Cell Exclusion Potentiates Antitumor Cytotoxicity in Fibrolamellar Carcinoma","author":"Carter","year":"2026","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101991_bib131","article-title":"DNAJ-PKAc induces metabolic rewiring and enhanced glutamine flux in fibrolamellar HCC","author":"Kamdar","year":"2025","journal-title":"J Hepatol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:25:57Z","timestamp":1786735557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926002624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":131,"alternative-id":["S2589555926002624"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101991","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of rare primary liver cancers: combined hepato-cholangiocarcinoma and fibrolamellar hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101991","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101991"}}